

August 05, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Receipt of Letter of Award from UNICEF for supply of bivalent Oral Polio Vaccine worth ~US\$ 8.205 million in Calendar Year 2028

Reg: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to our earlier letter dated October 03, 2025, wherein the Company informed that (i) it has received a Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF starting from 1st April 2026 to 31st March 2030; and (ii) the total award to the Company was for supply of bOPV in 10 and 20 dose presentation for a period of Q2 CY2026 and CY2027.

We are now delighted to inform you that in terms of the aforesaid Long-Term Agreement, the Company has received Letter of Award for supply of bOPV in 10 and 20 dose presentation worth ~US\$ 8.205 million (~Rs.78.24 Crore) in Calendar Year 2028.

The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and other circulars as may be applicable from time to time, is annexed herewith as **Annexure A**.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Ankit Jain
General Manager – Legal & Company Secretary

Annexure – A

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

#	Particulars	Details
a.	Name of the entity awarding the order(s) / contract(s)	United Nations International Children's Emergency Fund (UNICEF)
b.	Significant terms and conditions of order(s)/contract(s) awarded in brief	Award for supply of bivalent Oral Polio Vaccine (bOPV) by Panacea Biotec Limited in Calendar Year 2028 subject to applicable conditions.
c.	Whether order(s) / contract(s) have been awarded by domestic / international entity	International
d.	Nature of order(s) / contract(s)	Supply of bOPV to UNICEF vide Letter of Award received on 04.08.2026
e.	Whether domestic or international	International
f.	Time period by which the order(s) / contract(s) is to be executed	Calendar Year 2028
g.	Broad consideration or size of the order(s) / contract(s)	US\$8.205 million (~Rs.78.24 Crore)
h.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s) / contract(s)? If yes, nature of interest and details thereof	No
i.	Whether the order(s) / contract(s) would fall within related party transactions? If yes, whether the same is done at “arm’s length”	No

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Ankit Jain

General Manager – Legal & Company Secretary